Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

COVID-19 vaccines: the state of the art

Susan Levenstein, MD
Conditions
September 17, 2021
32 Shares
Share
Tweet
Share

Effective SARS-CoV-2 vaccines appeared in record time, with 68% of Italians, 60% of Americans, and 32% of all human beings already having at least one dose. Most of the 138 candidates quit by Phase 2; the German mRNA vaccine CureVac went through an entire Phase 3 trial before flaming out with only 48% efficacy.

WHO-approved

Pfizer-BioNTech: Its messenger RNA instructs our cells to fabricate spike protein, which stimulates the immune system. Overall efficacy against the wild strain was an astonishing 95% in Phase 3 trials, with Phase 4 effectiveness at least as good.

Protection is 95% against Alpha-variant COVID-19, 75% against Beta and probably Gamma. But it’s lower against Delta, especially long after vaccination, with reported effectiveness varying from 88% in England to 56% in Qatar and 42% from the Mayo Clinic.

The Israeli government supposedly estimated Pfizer’s protection against Delta at 41% to 64% overall, falling to a scary 16% six months after vaccination, and just 55% against severe disease in people over 65. But when an actual manuscript (click on “preliminary report” in this article) was prepublished, the numbers were less dire: people vaccinated in January were still 55% protected overall during July’s Delta surge, 86% against severe COVID-19.

Moderna: This mRNA vaccine was 94% effective in Phase 3 trials, 100% against severe disease. Similar to Pfizer except, crucially, performing better against the Delta variant, with 86% effectiveness in Qatar and 76% in the Mayo Clinic.

The chief downside of both is the low storage temperatures, an absurd -70º C. for Pfizer. Though that’s sometimes now considered -20º the cold chain is still a barrier, especially in the developing world, as is high cost.

Rare complications include anaphylaxis (10 per million doses), possibly Bell’s palsy, and, unfortunately, cardiac reactions: myocarditis, usually in young men after dose two, pericarditis in older men (10 and 18 cases per million). Almost none have been fatal, and the risk to the heart from COVID-19 itself is far greater.

AstraZeneca: Uses a harmless adenovirus to deliver the spike protein to the immune system. AstraZeneca is cheap and easy to handle. But the methodology behind its chief Phase 3 report was embarrassingly poor, overall efficacy was only 59% in young volunteers, and it is uniquely ineffective against asymptomatic infection.

A better U.S. trial reportedly shows (from press releases) that AstraZeneca works reasonably well, at all ages, if the second dose is given after 4 weeks. Astonishingly, the investigators tried to fudge these results, despite knowing they would be scrutinized with a fine-tooth comb, and had to adjust their top-line efficacy from 79% to 76%.

I emphasize dose timing because a U.K. study claiming AstraZeneca worked better with 12 weeks between doses convinced many countries to institute that gap. Real-world research has shown, though, that one dose protected elderly Scots only 70% against severe COVID-19, and older English only 80% even with two doses – the mRNA vaccines are 90-100%.

Unfortunately, European countries didn’t take the hint from the U.S. trial, maintaining 10-12-week gaps between doses. (The U.K. kept Pfizer at 12 weeks as well, even after demonstrating lower effectiveness.)

AstraZeneca works against Alpha and Gamma but so miserably against Beta (10% efficacy) that South Africa canceled its orders. Against Delta, the estimated effectiveness is 60%.

Vaccine-induced thrombotic thrombocytopenia, especially dangerous cerebral bleeds, first emerged in early March, perhaps as frequently as one in 26,000 doses. U.K. officials steadfastly denied seeing such complications until they “fessed up” a month later — eventually admitting there had been 242 cases, 49 fatal. Most occur under age 50, so Europe began giving AstraZeneca (and J&J) only to older people. Particularly wrong-headed because, as I just pointed out, AstraZeneca performs less well in the elderly using the European 10-12-week schedule.

Johnson & Johnson/Janssen: A viral vector vaccine marketed as a single dose, with overall efficacy peaking at 66% after four weeks. J&J shares AstraZeneca’s clotting problems, association with Guillain-Barré syndrome, and likely low effectiveness against Delta. But it’s better against Beta (64% vs. 10%) and asymptomatic infection (74% vs. 2% [stet]).

SinoPharm and Sinovac: Chinese attenuated virus vaccines. Sinopharm’s Phase 3 trial claimed 78% efficacy, and it is being used widely. The low efficacy of Sinovac’s CoronaVac, 51% in one Phase 3 trial, 42% against Gamma, and low antibodies against Delta, may have contributed to many countries’ surges.

Phase 3 trials, no WHO approval

Novavax: A protein subunit vaccine. Results of Phase 3 trials in the U.K. (published) and North America (announced) showed 90% efficacy. Only 50% against Beta, though, and we know nothing about Delta.

Sputnik V: A viral vector vaccine. Its interim Phase 3 report claimed 91% efficacy, but odd discrepancies justify skepticism; Russia has denied access to raw data. Sputnik also has a quality control issue, with Brazil and Slovakia rejecting bad batches.

No detailed Phase 3 reports

CanSino: A viral vector vaccine used in China, Pakistan, and Mexico, supposedly 66% effective.

Covaxin: An Indian killed coronavirus vaccine, used by a dozen countries after claims of 78% efficacy.

Abdala: Cuba says its protein subunit vaccine is 92.8% effective.

Issues

Holy Grail: mRNA vaccines can be engineered to target a specific variant. Some think it might be feasible to create a universal vaccine effective against all SARS-CoV-2 strains past or future.

Hesitancy: In the highly politicized U.S., giant surges in undervaccinated red states have barely budged no-vax sentiment, though it’s falling abroad. Except in Russia, where vaccine refusal long predates COVID-19, and the skepticism rate is 47%. Germany has the highest rate in Western Europe (19%), Spain the lowest (9%).

Novaxxers most often say the vaccines are “experimental”; others fear side effects, think they’re invulnerable, or believe bizarre conspiracy theories. So the most urgent move is in the hands of the FDA (for Pfizer, mission accomplished) and the EMA: give full rather than emergency approval. Green Passes and mandates are also persuasive. Access issues must be overcome, including by ensuring truly cost-free vaccination in the U.S., where one in four workers have no paid sick leave.

Mix-n-match: Most European countries now give Pfizer or Moderna second doses to people who first received AstraZeneca – mainly to avoid clotting complications, but likely enhancing efficacy, including against Delta.

Boosters: Antibody levels fall, and breakthrough infections rise by six months after vaccination, so most experts think we will eventually all need boosters, ideally universal or variant-engineered. (Beware – the word “booster” is sometimes erroneously used for the 3rd dose the immunosuppressed need to jump-start their immune system.) Should we be giving another dose to people vaccinated in early 2021? Israel already is, claiming rapidly enhanced effectiveness; the U.S. and Europe will follow suit. A post-Johnson & Johnson booster also makes sense, either with J&J or an mRNA vaccine.

The more SARS-CoV-2 around, the more likely new variants will arise, making it especially imperative to vaccinate developing countries. But I can’t fully agree boosters are unethical when fewer than 5% of Africans have had even one dose. Given the falloff in protection over time, boosters for the elderly and chronically ill who were first to be vaccinated are appropriate and timely.

This article was originally published, in English and Italian, in the journal Epidemiologia & Prevenzione.

Susan Levenstein is an internal medicine physician and author of Dottoressa: An American Doctor in Rome.

Image credit: Shutterstock.com

Prev

Dying after leaving against medical advice [PODCAST]

September 16, 2021 Kevin 0
…
Next

There is nothing soft about "soft skills"

September 17, 2021 Kevin 0
…

Tagged as: COVID, Infectious Disease

Post navigation

< Previous Post
Dying after leaving against medical advice [PODCAST]
Next Post >
There is nothing soft about "soft skills"

More by Susan Levenstein, MD

  • An update on COVID’s long tail

    Susan Levenstein, MD
  • A summary of state of the art COVID treatment

    Susan Levenstein, MD
  • COVID-19 in Italy: the good, the bad, and the ugly

    Susan Levenstein, MD

Related Posts

  • How to get patients vaccinated against COVID-19 [PODCAST]

    The Podcast by KevinMD
  • COVID-19 divides and conquers

    Michele Luckenbaugh
  • State sanctioned executions in the age of COVID-19

    Kasey Johnson, DO
  • To treat future COVID variants, we need more than vaccines

    Ian Chan, MBA
  • A patient’s COVID-19 reflections

    Michele Luckenbaugh
  • Starting medical school in the midst of COVID-19

    Horacio Romero Castillo

More in Conditions

  • Urgent innovation needed to address growing mental health crisis among children and families

    Monika Roots, MD
  • The importance of listening in health care: a mother’s journey advocating for children with chronic Lyme disease

    Cheryl Lazarus
  • The unjust reality of racial disparities in pediatric kidney transplants

    Lien Morcate
  • The surprising medical mystery of a “good” Hitler: How a rescued kitten revealed a rare movement disorder

    Teresella Gondolo, MD
  • The power of coaching for physicians: transforming thoughts, changing lives

    Kim Downey, PT
  • Unlocking the secrets of cancer conferences: an end-of-life counselor’s journey among pharmaceutical giants

    Althea Halchuck, EJD
  • Most Popular

  • Past Week

    • Physician entrepreneurs offer hope for burned out doctors

      Cindy Rubin, MD | Physician
    • Why doctors aren’t to blame for the U.S. opioid crisis [PODCAST]

      The Podcast by KevinMD | Podcast
    • The power of coaching for physicians: transforming thoughts, changing lives

      Kim Downey, PT | Conditions
    • The hidden factor in physician burnout: How the climate crisis is contributing to the erosion of well-being

      Elizabeth Cerceo, MD | Physician
    • Unlocking the secrets of cancer conferences: an end-of-life counselor’s journey among pharmaceutical giants

      Althea Halchuck, EJD | Conditions
    • We need a new Hippocratic Oath that puts patient autonomy first

      Jeffrey A. Singer, MD | Physician
  • Past 6 Months

    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • Breaking point: the 5 reasons American doctors are dreaming of walking away from medicine

      Amol Shrikhande, MD | Physician
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
    • Unveiling the hidden damage: the secretive world of medical boards

      Alan Lindemann, MD | Physician
  • Recent Posts

    • Healing trauma and reconnecting: Unmasking the impact of dissociation [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why the WHO’s pandemic accord is critical for global health care

      Elizabeth Métraux | Policy
    • The revolutionary Kaiser-Geisinger deal: How health care giants are reshaping the industry and empowering patients

      Robert Pearl, MD | Policy
    • The escalating violence in health care workplaces: a critical problem facing the nation’s health care system

      Harry Severance, MD | Physician
    • Is chaos in health care leading us towards socialized medicine? How physician burnout is a catalyst.

      Howard Smith, MD | Physician
    • A pediatrician’s journey into integrative medicine [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 1 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • Could Semaglutide Help Curb Addictive Behaviors?
  • 'If the Narcan Isn't Working, Give More' and Other Myths About Naloxone Use
  • CDC: Children's Brain Infections Rose Last Winter, But Remained Rare
  • Inside the Fight Against Burnout Amid the Chaos of War in Ukraine
  • Cardiovascular Risk Models Still Fall Short for Arthritis Patients

Meeting Coverage

  • Cardiovascular Risk Models Still Fall Short for Arthritis Patients
  • De-Escalated Surgery Suffices for Low-Risk Cervical Cancer
  • More Evidence Backs Gout Benefit for Gliflozin Agents
  • Reaction to FDA's Approval of Upadacitinib for Crohn's Disease
  • CDK4/6 Extends Reach Into Early-Stage Breast Cancer
  • Most Popular

  • Past Week

    • Physician entrepreneurs offer hope for burned out doctors

      Cindy Rubin, MD | Physician
    • Why doctors aren’t to blame for the U.S. opioid crisis [PODCAST]

      The Podcast by KevinMD | Podcast
    • The power of coaching for physicians: transforming thoughts, changing lives

      Kim Downey, PT | Conditions
    • The hidden factor in physician burnout: How the climate crisis is contributing to the erosion of well-being

      Elizabeth Cerceo, MD | Physician
    • Unlocking the secrets of cancer conferences: an end-of-life counselor’s journey among pharmaceutical giants

      Althea Halchuck, EJD | Conditions
    • We need a new Hippocratic Oath that puts patient autonomy first

      Jeffrey A. Singer, MD | Physician
  • Past 6 Months

    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • Breaking point: the 5 reasons American doctors are dreaming of walking away from medicine

      Amol Shrikhande, MD | Physician
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
    • Unveiling the hidden damage: the secretive world of medical boards

      Alan Lindemann, MD | Physician
  • Recent Posts

    • Healing trauma and reconnecting: Unmasking the impact of dissociation [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why the WHO’s pandemic accord is critical for global health care

      Elizabeth Métraux | Policy
    • The revolutionary Kaiser-Geisinger deal: How health care giants are reshaping the industry and empowering patients

      Robert Pearl, MD | Policy
    • The escalating violence in health care workplaces: a critical problem facing the nation’s health care system

      Harry Severance, MD | Physician
    • Is chaos in health care leading us towards socialized medicine? How physician burnout is a catalyst.

      Howard Smith, MD | Physician
    • A pediatrician’s journey into integrative medicine [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

COVID-19 vaccines: the state of the art
1 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...